Splenic marginal zone lymphoma with and without villous lymphocytes

Current Treatment Options in Oncology

Volumn 8, Issue 2, 2007, Pages 109-116

  Matutes, Estella ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALKYLATING AGENT; ALPHA2B INTERFERON; CHLORAMBUCIL; CLADRIBINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; HAEMOPHILUS VACCINE; PENICILLIN G; PENTOSTATIN; PNEUMOCOCCUS VACCINE; RIBAVIRIN; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; B CELL LYMPHOMA; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOPENIA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; HEPATITIS C; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MONOTHERAPY; OVERALL SURVIVAL; PATIENT MONITORING; SPLENECTOMY; SPLENIC LYMPHOMA WITH VILLOUS LYMPHOCYTES; SPLENIC MARGINAL ZONE LYMPHOMA; SPLENOMEGALY; STREPTOCOCCUS INFECTION; SURVIVAL RATE; TREATMENT RESPONSE; B LYMPHOCYTE; PATHOLOGY; REVIEW; SPLEEN TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; HUMANS; INTERFERON ALFA-2B; LYMPHOMA, B-CELL; RIBAVIRIN; SPLENECTOMY; SPLENIC NEOPLASMS;

EID: 38149086707     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-007-0026-0     Document Type: Article

References (34)

1. Isaacson PG, Piris MA, Catovsky D, et al.: Splenic marginal zone cell lymphoma. In: Jaffe ES, Harris N, Vardiman JW editors. Tumours of Haemopoietic and lymphoid tissues. World Health Organization Classification of tumours Lyon, France: IARC Press; 2001, 135-137
2. Catovsky D, Matutes E: Splenic lymphoma with circulating villous lymphocytes/splenic marginal zone lymphoma. Semin Hematol 1999, 36: 148-154
3. Arcani L Paulli M, Boveri E, et al.: Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic features. Cancer 2004, 100: 107-115
4. Mele A, Pulsoni A, Bianco E, et al.: Hepatitis C virus and B-cell non-Hodgkin lymphomas: An Italian multicenter case-control study. Blood 2003, 102:996-999.
5. Isaacson PG, Matutes E, Burke M, Catovsky D The histopathology of splenic lymphoma with villous lymphocytes. Blood 1994, 84:3828-3834.
6. Mateo M, Mollejo M, Villuendas R, et al.: 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol 1999, 154:1583-1589.
7. Gruszka-Westwood AM, Matutes E, Coignet LJA, et al.: The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: A study by FISH. Br J Haematol 1999;104:600-604.
8. Gruszka-Westwood AM, Hamoudi RA, Matutes E, et al.: P53 abnormalities in splenic lymphoma with villous lymphocytes (SLVL). Blood 2003; 97:3552-3558.
9. Thieblemont C, Felman P, Callet-Bauchu E, et al.: Splenic marginal zone lymphoma: A distinct clinical and pathological entity. The Lancet Oncol 2003; 4: 95-103
10. Arcaini L, Lazzarino M, Colombo N et al.: Splenic marginal zone lymphoma: A prognostic model for clinical use. Blood 2006, 107: 4643-4649
11. Chacon J, Mollejo M, Munoz E et al.: Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002, 100: 1648-1654
12. Troussard X, Valensi F, Duchayne E, et al.: Splenic lymphoma with villous lymphocytes. Clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol. 1996; 93:731-736.
13. Iannitto E, Ambrosetti A, Ammatuna E, et al.: Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients. Cancer 2004; 101:2050-2057.
14. Parry-Jones N, Matutes E, Gruszka-Westwood AM, et al.: Prognostic features of splenic lymphoma with villous lymphocytes: A report on 129 patients. Br J Haematol 2003, 120: 759-764
15. Camacho FI, Mollejo M, Mateo MS, et al.: Progression to large B-cell lymphoma in splenic marginal zone lymphoma: A description of a series of 12 cases. Am J Surg Pathol 2001, 25: 1268-1276
16. Mulligan SP, Matutes E, Dearden C, et al.: Splenic lymphoma with villous lymphocytes: Natural history and response to therapy in 50 cases. Br J Haematol 1991;78:206-209.
17. Franco V, Florena AM, Stella M, et al.: Splenectomy influences bone marrow infiltration in patients with splenic marginal zone lymphoma with or without villous lymphocytes. Cancer 2001; 91:294-301.
18. Bolam S, Orchard J, Oscier D: Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol 1997; 99:158-161.
19. Yasukawa M, Yamaguchi H, Azuma T, et al.: Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes. Eur J Haematol 2002; 69:112-114.
20. Lefrere F, Levy V, Francois S, et al.: Fludarabine treatment in patients with splenic lymphoma with villous lymphocytes: An update. Leukemia 2004, 18: 1924-1925
21. Virchis A, Mehta A: Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-CDA). Br J Haematol 1998; 100:609.
22. Riccioni R, Caracciolo F, Galimberti S, et al.: Low dose 2-CDA schedule activity in splenic marginal zone lymphomas. Hematol Oncol 2003; 21:163-168.
23. Lefrere F, Hermine O, Francois S, et al.: Lack of efficacy of 2-chlorodeoxyadenosine in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 2000, 40:113-117.
24. Delanoy A: 2 chlorCdeoxyadenosine: clinical applications in hematology. Blood Rev 1996, 10:148-166.
25. Iannitto E, Minardi V, Calvaruso G, et al.: Deoxycoformycin (penttostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. Eur J Haematol 2005, 75:130-135.
26. Fabbri A, Gozetti A, Lazzi S, et al.: Activity of rituximab in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Clin Lymphoma Myeloma 2006, 6:496-499.
27. Bennett M, Sharma K, Yegena S, et al.: Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica 2005, 90: 856-858
28. Arcaini L, Orlandi E, Scotti M, et al.: Combination of rituximab, cyclophosphamide and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma 2004; 4:250-252.
29. Tsimberidou AM, Catovsky D, Schlette E, et al.: Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with Rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006, 107: 125-135
30. Hermine O, Lefrere F, Bronowicki JP, et al.: Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002, 347: 89-94
31. Vallisa D, Bernuzzi P, Arcaini L, et al.: Role of anti-hepatitis C virus (HCV) treatment in HCV-related low grade B-cell non-Hodgkin's lymphoma: A muticenter Italian Experience. J Clin Oncol 2005, 23:468-473.
32. Keladi C, Rollor F, Park S, et al.: Response to antiviral treatment in hepatitis C virus associated marginal zone lymphomas. Leukemia 2004, 18:1711-1716.
33. Osuji NC, del Guidice I, Matutes E, et al.: The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005, 90:1435-1436.
34. Thornton PD, Matutes E, Bosanquet AG, et al.: High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann. Haematol 2003; 82:759-765.